

This guide¹ is a reference tool for the assessment and management of potential donors in confirmed cases of death determination by neurologic criteria (DNC) or in cases where a decision to cease active treatment has been made. An integrated approach to the care team's clinical judgment remains essential.

MINIMUM MONITORING REQUIRED

- Cardiac monitor
- Arterial cannula; note the blood pressure (BP) q1h
- Continuous oxygen saturation (SaO₂); note the saturation q1h
- Urinary catheter, strict control of intake and output; note the diuresis q1h
- Continuous or minimal core temperature q4h

ASSESSMENT OF POTENTIAL DONOR

Initial assessment

Identifying or retrieval centre

- FSC, Na, K, Cl, Glucose, Urea, Creatinine, PTT, INR, Ca, Mg, PO₄, Lactate, Albumin and Protein
- AST, ALT, Alkaline phosphatase, Total and direct bilirubin, GGT, LDH, Amylase, Lipase
- CK, CKMB or Troponin I/T
- Glycated hemoglobin (HbA1c)
- Arterial blood gas
- Blood culture x 2 series
- Blood group and antibodies search
- Crossmatch (packed red blood cells in reserve, according to the care team responsible for retrieval)
- Serology, virology and histocompatibility managed by Transplant Québec
- Urinalysis, including microalbumin/creatinine ratio and protein/creatinine ratio
- Urine culture
- Sputum gram stain and culture on bronchial or endotracheal secretions
- Weight / Height
- Chest X-ray
- Abdominal ultrasound, if requested by Transplant Québec
- Abdominal and thoracic CT-scan, if requested by Transplant Québec

q. 8 h

CK, CKMB or Troponin I/T q8h x 24h
If patient unstable, pursue q8h

q. 12 h

AST, ALT, Alkaline phosphatase, Total and direct bilirubin, GGT, LDH, Amylase, Lipase, Na, K, Glucose, Urea, Creatinine, FSC, PTT, INR, Lactate, Arterial blood gas

q. 24 h

Cl, Mg, Ca, PO₄

PRN

If clinical signs of infection are present, repeat:
Blood culture x 2 series, Gram and bronchial sputum culture, Urine culture

Specific assessment of a potential heart donor*

- EKG QD
- Echocardiogram to carry out according to the orders of the cardiac program and after DNC determination
- Avoid administering significant inotrope support
- Notify if inotrope needs increase



* Use IV in-line filter if donor presents a patent foramen ovale or an atrial septal defect (ASD).

Specific assessment of a potential lung donor

- Arterial blood gas ± q2h using a **hyperoxygenation test***
- Chest X-ray QD
- Bronchoscopy, if requested by Transplant Québec



* Hyperoxygenation test

- ▶ Ventilate with 100% FiO₂, minimum PEEP of 5 cm H₂O and tidal volume of 8 mL/kg of ideal weight
- ▶ Arterial blood gas after 20 minutes
- ▶ **Pulmonary recruitment maneuvers** PRN

¹ Ref.: Ball IM, Hornby L, Rochweg B, et al. *Management of the neurologically deceased organ donor: A Canadian clinical practice guideline*. CMAJ. 2020 April 6;192(14):E361-E369. DOI:10.1503/cmaj.190631. | Nakagawa TA, Shemie SD, Dryden-Palmer K, Parshuram CS, Brierley J. *Organ Donation Following Neurologic and Circulatory Determination of Death*. *Pediatric Critical Care Medicine*. 2018;19:S26-S32. DOI:10.1097/PCC.0000000000001518.1. | Weiss MJ, Blanco AP, Ben Gelbart. *Special issues in pediatric deceased organ donation*. *Intensive Care Medicine*. February 2019;1-3. DOI:10.1007/s00134-019-05523-2.

MANAGEMENT OBJECTIVES AND RECOMMENDATIONS

Hemodynamics

D5% NaCl 0.9% or 0.45% or RL
depending on sodium level

+

KCl depending on potassium level
Rate according to maintenance needs
Adjust according to urine output

General objectives

- Target euolemia¹
- Normal HR and BP according to age group
(see *Heart rate and blood pressure*)

If hypotension and signs of hypovolemia

Bolus NaCl 0.9 % IV 10 mL/kg
q15 min x 3
or Ringer's Lactate or albumin 5%² PRN

If hypotension

1. Vasopressin³ 0.0003-0.0007 U/kg/min
 2. Norepinephrine 0.05-0.2 µg/kg/min
 3. Epinephrine 0.05-0.2 µg/kg/min
- If indicated: Hydrocortisone 1 mg/kg IV
q6h max 50 mg per dose

If hypertension⁴ according to age group

- 0-3 months BP > 90/60 mmHg
- 3 months-1 year BP > 110/70 mmHg
- 1-12 years BP > 130/80 mmHg
- 12-18 years BP > 140/90 mmHg

1. Wean vasopressors/inotropes
2. Nitroprusside 0.5-5.0 µg/kg/min
and/or
3. Esmolol 100-500 µg/kg bolus
followed by 100-300 µg/kg/min IV infusion

Heart rate and blood pressure

Age group	HR (beats per minute)	Systolic / diastolic BP
• 0-3 months	• 100-150	• 65-85 / 45-55 mmHg
• 3-6 months	• 90-120	• 70-90 / 50-65 mmHg
• 6-12 months	• 80-120	• 80-100 / 55-65 mmHg
• 1-3 years	• 70-110	• 90-105 / 55-70 mmHg
• 3-6 years	• 65-110	• 95-110 / 60-75 mmHg
• 6-12 years	• 60-95	• 100-120 / 60-75 mmHg
• > 12 years	• 55-85	• 110-135 / 65-85 mmHg

¹ The rate and type of IV fluids may vary according to serum sodium and potassium levels, enteral nutrition tolerance, and should target homeostasis.

² The use of hydroxyethyl starch products should be avoided when there is renal insufficiency.

³ Prioritize Vasopressin for hemodynamically unstable patients, except if instability is primarily due to left ventricular dysfunction.

⁴ It is recommended to monitor volume status prior to administering beta blockers.

Cardiac dysfunction

Indicated by

Echocardiogram with ejection fraction (LVEF) < 50%
or hemodynamic instability
Shock unresponsive to reestablishment of volume
status and that requires vasoactive support
(epinephrine 0.2 µg/kg/min or more)

At the request
of the care team, initiate
hemodynamic monitoring
(intermittent or
continuous)
including, but not
limited to:

- Targeted
echocardiogram*
- or
- Other non-invasive
procedures for cardiac
output monitoring

Hemodynamic
management
according
to standard
care practices
(consider
using inotropes)

* Note that targeted echocardiograms are not intended as
substitutes for trans-thoracic echocardiograms (TTE).

Mechanical ventilation

Objectives

- Minimal FiO₂ to maintain
SaO₂ ≥ 95%
- pH 7.35-7.45
- PaCO₂ 35-45 mmHg
- Tidal volume (TV)
5-8 mL/kg of ideal weight
- PEEP ≥ 5 cm H₂O
- Peak inspiratory pressure (PIP)
≤ 30 cm H₂O

Clinical surveillance

Endotracheal
suctioning
q8h and PRN
Avoid pulmonary
edema
Head of bed elevated
at 30°
Turn and position q2h

Pulmonary recruitment maneuvers

Lungs previously deemed inadmissible for transplant may benefit
from recruitment maneuvers to regain function. Refer to the
hospital's internal protocol, if applicable.

The care team may also consult Transplant Québec, if needed.

PEDIATRIC POTENTIAL ORGAN DONOR ASSESSMENT AND MANAGEMENT DEATH DETERMINATION BY NEUROLOGIC CRITERIA (DNC)

For children weighing over 60 kg or in puberty, please view the adult donor guide.

Temperature

Objective	
Core T° 35.0 to 37.5°C*	
< 35.0 °C	> 38.0 °C
<ul style="list-style-type: none"> Warming blanket Cover the head 	<ul style="list-style-type: none"> Septic profile Empiric broad-spectrum antibiotics, at the request of the care team

* Ensure a core temperature of $\geq 36.0^{\circ}\text{C}$ during death determination by neurologic criteria (DNC).

Diuresis

Objective	
0.5-3.0 mL/kg/h	
Oliguria	Polyuria
If urine output < 0.5 mL/kg/h: NaCl 0.9% bolus (10 mL/kg), repeat PRN	If urine output > 4 mL/kg/h Rule out diabetes insipidus*
If urine output < 0.5 mL/kg/h Rule out secondary causes (postrenal obstruction) Rule out low cardiac output and/or hypovolemia (see <i>Cardiac dysfunction</i>)	DDAVP 0.25-1.0 µg IV q6h or nasal spray or Use vasopressin as first choice if hemodynamic support required (0.0003-0.0007 U/kg/min IV infusion max. 2.4 U/h)



* Diabetes insipidus:
Urine output > 4 mL/kg/h,
Na ≥ 145 mmol/L,
serum osmolality
 ≥ 300 mOsm, urine
osmolality ≤ 200 mOsm,
urine specific gravity
< 1.005.

Glycemia

Objective
6-10 mmol/L
Capillary blood glucose* q1h
Insulin infusion PRN

* If capillary blood glucose within normal range and stable, levels may be monitored q2h, then q4h.

Electrolytes

Objectives
Na 135-155 mmol/L
K 3.5-5.0 mmol/L
Mg 0.65-1.05 mmol/L
PO ₄ 0.74-1.52 mmol/L
Ca 2.2-2.6 mmol/L
Correct electrolyte abnormalities

Prophylaxis

Pharmacological thromboprophylaxis according to clinical context or, if contraindicated, use mechanical thromboprophylaxis.

Nutrition

Standard tube feeding according to the hospital's protocol

Do not initiate parenteral nutrition. However, do not discontinue if already initiated.

Coagulation and hematology

Objectives
<ul style="list-style-type: none"> Optimal hemoglobin > 70 g/L Administer platelets and fresh frozen plasma if clinical signs of hemorrhage or coagulopathy Preventive administration of blood products is discouraged CMV-negative blood is <u>not required</u>



Contact Transplant Québec prior to administering blood products that may interfere with plasma dilution.

Eye care

Keep eyelids closed

Avoid oily or greasy substances

The Transplant Québec team wishes to thank everyone who contributed to the revision of this document.

To download or print the guide:

<https://www.transplantquebec.ca/en/procedures-and-forms>

This document is overseen by Transplant Québec and is revised periodically.

Please ensure that you have the most recent version available on the website.